Natdecita 50 mg Injection

Description

Natdecita 50 mg Injection contains Decitabine, a hypomethylating antineoplastic agent used in the treatment of myelodysplastic syndromes (MDS) and related bone marrow disorders. It helps restore normal gene function in abnormal cells, improves blood cell production, and slows disease progression. Natdecita is administered intravenously under strict medical supervision.

Benefits

• Improves production of healthy blood cells

• Reduces dependence on blood transfusions

• Slows progression of myelodysplastic syndromes

• Helps restore normal gene function in bone marrow cells

• Proven treatment option for high-risk MDS patients

Indications and Usage

atdecita 50 mg Injection is indicated for the treatment of:

• Myelodysplastic Syndromes (MDS)

  • Refractory anemia

  • Refractory anemia with ringed sideroblasts

  • Refractory anemia with excess blasts

  • Refractory anemia with excess blasts in transformation

• Chronic Myelomonocytic Leukemia (CMML)

• Patients classified as Intermediate-2 or High-Risk (IPSS)

• De novo or secondary MDS, previously treated or untreated

Treatment must be initiated and supervised by an oncologist or hematologist.

How it Works

Decitabine inhibits DNA methyltransferase, leading to DNA hypomethylation. This restores normal control of cell growth and differentiation in abnormal bone marrow cells and induces cell death in rapidly dividing cancer cells.

Dosage & Administration

Natdecita 50 mg Injection is administered intravenously by trained healthcare professionals only.

Recommended regimens:

Regimen 1

• 15 mg/m² IV infusion over 3 hours

• Every 8 hours for 3 days

• Repeated every 6 weeks

Regimen 2

• 20 mg/m² IV infusion over 1 hour

• Once daily for 5 days

• Repeated every 4 weeks

• A minimum of 4 treatment cycles is recommended

• Dose adjustments may be required based on blood count recovery

• Regular monitoring of CBC, platelets, liver and kidney function is mandatory

Side Effects

Common side effects:

• Neutropenia

• Thrombocytopenia

• Anemia

• Fatigue

• Fever

• Nausea

• Diarrhea or constipation

• Cough

• Hyperglycemia

Serious side effects:

• Severe infections

• Febrile neutropenia

• Severe bleeding

• Liver function abnormalities

• Pulmonary edema

• Cardiac rhythm disturbances

• Intracranial hemorrhage

Warning and Precaution

• Causes severe neutropenia and thrombocytopenia

• High risk of infections – early use of antibiotics or growth factors may be required

• Not recommended during pregnancy – may cause fetal harm

• Women should avoid pregnancy during treatment and for 1 month after

• Men should avoid fathering a child during treatment and for 2 months after

• Use caution in patients with liver or kidney impairment

• Not to be used in uncontrolled infections

• Cytotoxic drug – proper handling and disposal required

Patient Guidance

Natdecita 50 mg Injection is a prescription-only oncology medicine and must be administered in a hospital or oncology center by trained healthcare professionals. Treatment decisions should be made by a qualified oncologist or hematologist.